Quia Timet Patent Injunction Stops Intas’s Dabrafenib Launch
Novartis AG sought a quia timet patent injunction against Intas Pharmaceuticals Limited before the Delhi High Court, alleging that regulatory filings and an investigation report revealed imminent infringement…